Antiplatelet therapy in secondary stroke prevention
This article focuses on recent data about the safety and effectiveness of antiplatelet therapies for secondary stroke prevention. Highlights include a discussion of changes in the professional labeling for aspirin and the results of a low- versus high-dose aspirin trial (Aspirin after Carotid Endarterectomy trial). Safety issues regarding aspirin also are considered. Other topics include a review of recent data on thrombotic thrombocytopenic purpura (TTP) associated with ticlopidine and a brief update on clopidogrel. A summary of discussions related to the European Stroke Prevention Study 2 data and Food and Drug Administration consideration of combination dipyridamole/aspirin therapy are presented.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Food and Drug Administration: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register October 23, 1998, 63(205):56802–56819.Google Scholar
- 7.ISIS-2 (Second International Study of Infarct Survival) Collabora-tive Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349–360.Google Scholar
- 8.Antiplatelet Trialists: Collaboration secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988, 296:320–331.Google Scholar
- 9.UK TIA Study Group, A United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: interim results. BMJ 1988, 296:316–320.Google Scholar
- 20.Svenson CK: Representation of American blacks in clinical trials of new drugs. JAMA 1989, 29:415–421.Google Scholar
- 23.Ticlopidine revised package insert: Roche Laboratories. 2 June, 1998.Google Scholar
- 30.US Department of Health and Human Services: Public Health Service; Food and Drug Administration — Center for Drug Evaluation and Research. Clopidogrel bisulfate [Application #020839]. The Electronic Orange Book. Last Updated: September 07, 1999.Google Scholar
- 32.FDA press release. Aggrenox™ (Dipyridamole/aspirin) capsule[Original Application #020884]. 15 June 1999.Google Scholar
- 33.Open Public Hearing of the Peripheral and Central Nervous System Advisory Committee: Issue: Safety and Efficacy of Aggrenox™ (Dipyridamole/aspirin) capsule [NDA 20-884]. Wednesday April 28, 1999.Google Scholar